Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 4, 2023 -- For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or ATM, RB1, FANCC, and ERCC2) or increased tumor mutational burden. There was an association noted between the baseline and on-treatment immune contexture with clinical outcomes.
"Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint," Galsky said in a statement. "If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
NECTIN4 Amplifications Predict Outcomes in Metastatic Urothelial Cancer
WEDNESDAY, May 8, 2024 -- For patients with metastatic urothelial cancer (mUC), NECTIN4 amplifications predict anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV)...
FDA Approves Anktiva for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer
FRIDAY, April 26, 2024 -- The U.S. Food and Drug Administration has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for th...
Survival Up With Enfortumab Vedotin + Pembrolizumab in Urothelial Cancer
FRIDAY, March 8, 2024 -- For patients with previously untreated locally advanced or metastatic urothelial carcinoma, enfortumab vedotin and pembrolizumab yield significantly...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.